81.04 -0.17 (-0.21%)
After hours: 5:19PM EDT
|Bid||81.03 x 200|
|Ask||81.20 x 1000|
|Day's Range||80.45 - 81.95|
|52 Week Range||63.76 - 86.27|
|PE Ratio (TTM)||8.82|
|Forward Dividend & Yield||2.08 (2.59%)|
|1y Target Est||N/A|
The FDA has approved a new cancer treatment developed by Gilead's $11B acquisition Kite Pharma. Yahoo Finance’s Alexis Christoforous, Rick Newman, and Nicole Sinclair have more.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Gilead Sciences, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
Celgene's partnership strategy gives it exposure to multiple companies' research on next-generation cell therapy.
Gilead Sciences' Kite will make a futuristic one-time dose that claims to cure a rare blood cancer in a few weeks. It costs about a third of a million dollars.
Gilead jumped early Thursday after the FDA approved its CAR-T drug, dubbed Yescarta, to treat Non-Hodgkin lymphoma.
The U.S. Food and Drug Administration approved Wednesday Gilead Sciences, Inc. (NASDAQ: GILD )'s therapy for the treatment of non-Hodgkin's Lymphoma (NHL) called YESCARTA. The announcement helped boost ...
During the past six months or so, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has been regaining some of its footing. CEO Joe Papa has wasted little time in cutting costs, streamlining the business and unloading of VRX stock’s assets. Since April, VRX stock has rallied from $8.60 to $12.81.
Less than two months ago, Gilead Sciences (GILD) announced an almost $12 billion deal to buy Kite Pharma. Late yesterday, the FDA approved Kite’s CAR-T cancer therapy for adults with advanced lymphoma. It uses genetically-engineered T-cells to attack cancer cells, and it is only the second such therapy to make it through the FDA.
The drug is anticipated to rake in $1.7 billion in worldwide sales in the next five years with a U.S. list price of $373,000.
The Dow looks set to drop around 100 points as U.S. markets look to follow international stocks lower this morning. S&P 500 futures have fallen 0.5% , while Dow Jones Industrial Average futures have declined ...
Adobe Systems skyrocketed overnight on earnings guidance while eBay fell on its outlook. Gilead Sciences rallied on its big FDA win, also lifting Juno Therapeutics.
U.S. stock futures are tumbling on Thursday, and European stocks are sinking after Spain's central government said it would assume control of the region of Catalonia.
Gilead Sciences’ $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite’s flagship cell-therapy treatment for advanced lymphoma patients.
U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer. The Food and Drug Administration approved the gene therapy, to be sold under the name Yescarta, to treat adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments.
A new therapy for a type of lymphoma developed by Kite Pharma, which was acquired by Gilead Sciences Inc, won U.S. approval on Wednesday, marking the second approval for this potentially revolutionary approach to fighting cancer. Gilead said the price for the therapy with one-time administration would be $373,000. Gilead Sciences shares rose almost 4 percent to $83 in extended trading.
A new cancer therapy for a type of lymphoma developed by Kite Pharma, which was recently acquired by Gilead Sciences Inc, won U.S. Food and Drug Administration approval on Wednesday, six weeks ahead of ...